Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,459.62 -9.68 (-0.18%) Dow
38,981.78 -130.38 (-0.33%) Nasdaq
17,746.46 +28.81 (+0.16%) Bitcoin USD
61,577.45 -278.68 (-0.45%) CMC Crypto 200
1,280.03 -3.76 (-0.29%)
ITCI Dec 2024 75.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:38PM EDT. Market open.
| Previous close | 10.55 |
| Open | 8.00 |
| Bid | 6.40 |
| Ask | 7.80 |
| Strike | 75.00 |
| Expiry date | 2024-12-20 |
| Day's range | 7.30 - 10.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 141 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.